- Home
- EQV vs TBPH Comparison
EQV vs TBPH Comparison
Compare EQV & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQV
- TBPH
- Stock Information
- Founded
- EQV 2024
- TBPH 2013
- Country
- EQV United States
- TBPH United States
- Employees
- EQV N/A
- TBPH N/A
- Industry
- EQV
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- EQV
- TBPH Health Care
- Exchange
- EQV Nasdaq
- TBPH Nasdaq
- Market Cap
- EQV 465.8M
- TBPH 536.5M
- IPO Year
- EQV 2024
- TBPH N/A
- Fundamental
- Price
- EQV $10.41
- TBPH $10.90
- Analyst Decision
- EQV
- TBPH Strong Buy
- Analyst Count
- EQV 0
- TBPH 5
- Target Price
- EQV N/A
- TBPH $16.60
- AVG Volume (30 Days)
- EQV 27.2K
- TBPH 158.6K
- Earning Date
- EQV 01-01-0001
- TBPH 08-12-2025
- Dividend Yield
- EQV N/A
- TBPH N/A
- EPS Growth
- EQV N/A
- TBPH N/A
- EPS
- EQV N/A
- TBPH N/A
- Revenue
- EQV N/A
- TBPH $65,266,000.00
- Revenue This Year
- EQV N/A
- TBPH $51.74
- Revenue Next Year
- EQV N/A
- TBPH N/A
- P/E Ratio
- EQV $50.71
- TBPH N/A
- Revenue Growth
- EQV N/A
- TBPH 6.11
- 52 Week Low
- EQV $9.88
- TBPH $7.44
- 52 Week High
- EQV $10.74
- TBPH $11.88
- Technical
- Relative Strength Index (RSI)
- EQV N/A
- TBPH 45.21
- Support Level
- EQV N/A
- TBPH $10.90
- Resistance Level
- EQV N/A
- TBPH $11.26
- Average True Range (ATR)
- EQV 0.00
- TBPH 0.24
- MACD
- EQV 0.00
- TBPH -0.08
- Stochastic Oscillator
- EQV 0.00
- TBPH 2.00
About EQV EQV Ventures Acquisition Corp.
EQV Ventures Acquisition Corp is a blank check company.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).